The CYCLE‐AD (CYcling to Cease or Limit the Effects of Alzheimer’s Disease) research project is a randomized controlled trial designed to determine the impact of a home based, high intensity exercise intervention in healthy, cognitively intact individuals between the ages of 65 and 80 years who have a genetic risk for Alzheimer’s disease (AD). The CYCLE-AD trial will recruit otherwise healthy sedentary carriers randomized to one of two groups (n=75 each): 1) an Indoor Cycling (IC) group that participates in high-intensity interval training in their home using a commercially available Peloton® cycling system or 2) a Usual and Customary Care (UCC) group, in which participants engage in their habitual level of PA. We hypothesize that an 18-month high-intensity aerobic exercise regimen will slow AD-related disease progression in sedentary elders at genetic risk for AD. Participants in the intervention group will engage in exercise 3x/week (minimum 90 minutes/week) for 18 months. Primary outcome measures, obtained at study entry and at 18 months, will include comprehensive cognitive testing and brain MR imaging to assess disease progression and a comprehensive PA/fitness assessment to measure the degree of change in physical fitness due to high intensity aerobic exercise. The overall goal of the CYCLE-AD trial is to determine the role of long-term, high intensity exercise in slowing or delaying the onset of cognitive and AD-related brain changes in elders at genetic for AD. Successful translation and demonstration of the effectiveness of a scalable home-based exercise intervention capable of slowing or delaying disease onset will transform AD treatment, improve patient outcomes and quality of life, and reduce health care costs.
Stephen Rao, PhD
Jay L. Alberts, PhD
NIH 5R01AG070736, A Randomized Controlled Trial to Assess the Efficacy of Indoor Cycling in Slowing Disease Progression in Healthy Older Persons at Genetic Risk for Alzheimer’s Disease, Rao (PI) and Alberts (PI), 01/15/2021-12/31/2025.